Mubadala Investment Company, an Emirati state-owned funding company, will build a good manufacturing practice (GMP) facility to manufacture advanced biopharmaceuticals in Abu Dhabi, UAE.
The plant will be the first facility of its kind in the region to produce vital life science products for advanced biologics. It is intended to promote the UAE’s life sciences ecosystem.
Recommended White Papers
Recommended Buyers Guides
US-based pharmaceutical company National Resilience will operate the facility to produce a range of biopharmaceutical therapeutics for complex diseases, including cancer, infectious diseases, and inflammatory and autoimmune disorders. Resilience will contribute to the funding for the biopharma facility, in addition to equity investment from Mubadala.
Mubadala’s biopharma manufacturing project details
Mubadala will build a state-of-the-art biopharma campus, utilising the capabilities of its portfolio company Strata Manufacturing, an aero-structures manufacturing company.
Resilience will provide manufacturing, technology, and operational expertise for the biopharma facility and integrate the site as a node within its global network.
The two entities, Mubadala and Resilience, will use their respective capabilities to achieve standard goals, building a sustainable and knowledge-based economy for the UAE.
Details of Resilience’s biopharmaceutical solutions
Resilience has scalable manufacturing in five core modalities, namely Resilience Biologics, Resilience Cell Therapy, Resilience Gene Therapy, Resilience Nucleic Acids, and Resilience Vaccines. The company aims to advance these through emerging technologies and processes.
Biologics platforms are designed to enable antibody discovery companies, early-stage biopharma companies, and other biologics research teams to quickly move to first-in-human studies. They help in developing recombinant protein and monoclonal antibody treatments for both existing and new indications.
The company’s cell therapy technologies support the production of autologous immunotherapies (CAR-T, TCR, TIL), autologous haematopoietic stem cell therapies, or allogeneic regenerative medicines.
Resilience’s viral vector manufacturing platforms, process and analytical development (PAD) labs, GMP manufacturing services, and capacity are all designed to quickly move life-saving gene therapies from clinical to commercial scale.
The Resilience Nucleic Acids modality combines innovative processes and analytical development with molecular design and discovery to refine the development of advanced nucleic acid-based therapies. The specialities of the Resilience Vaccines modality include expertise in live viruses, viral vectors, oncolytic viruses and vectors, potency assays, virus-like particles (VLP), and antigen vaccines.
Marketing commentary on Mubadala
Mubadala aims to generate sustainable financial returns for the Government of Abu Dhabi. With a portfolio of AED1.04tn ($284bn), the company operates on six continents in a range of sectors and aims to promote sustainable growth and global integration of the UAE economy.
Mubadala will work to strengthen the UAE’s life sciences ecosystem by utilising UAE initiatives such as the Hope Consortium, an Abu Dhabi-led partnership that operates one of the most comprehensive end-to-end pharma supply chains on the market.
Marketing commentary on Resilience
National Resilience is a technology-focused biomanufacturing company based in California, US. The company works to extend the accessibility of complex medicines.
Founded in 2020, Resilience is building a sustainable network of end-to-end manufacturing solutions to ensure rapid, safe, and effective future treatments. The company operates 11 sites with one million square feet of total manufacturing space, employing 1,700 colleagues.
In November 2022, Resilience signed a deal with AstraZeneca to acquire the latter’s manufacturing facility in West Chester, Ohio, for the biomanufacturing of existing and emerging modalities.
The company has also collaborated with institutes and companies such as the California Institute for Regenerative Medicine (CIRM), Mayo Clinic, The Parker Institute for Cancer Immunotherapy (PICI), The University of Texas MD Anderson Cancer Center, Harward University, Takeda, and Bluebird Bio to expand its biomanufacturing technologies and capacity.
